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Abstract 
Objective:  Case  reports  showing  that  proton-pump  inhibitors  (PPIs),  omeprazole  and 
esomeprazole, can cause hypomagnesaemia have been accumulating since 2006. In this study, 
the reports submitted to the Adverse Event Reporting System (AERS) of the US Food and 
Drug Administration (FDA) were evaluated to assess omeprazole and esomeprazole in terms 
of susceptibility to hypomagnesaemia.  
Methods: After a revision of arbitrary drug names and the deletion of duplicated submis-
sions, the reports involving omeprazole and esomeprazole were analyzed. Standardized offi-
cial pharmacovigilance tools were used for the quantitative detection of a signal, i.e., an as-
sociation between a drug and an adverse drug event, including the proportional reporting 
ratio, the reporting odds ratio, the information component given by a Bayesian confidence 
propagation neural network, and the empirical Bayes geometric mean.  
Results: A total of 22,017,956 co-occurrences were found in 1,644,220 reports from 2004 to 
2009, where a co-occurrence was a pair of a drug and an adverse drug event. In total, 818 and 
743 adverse drug events were listed as omeprazole- and esomeprazole-associated, with 
hypomagnesaemia ranking 85
th and 135
th, respectively. Although both PPIs were associated 
with  hypomagnesaemia,  the  statistical  metrics  suggested  that  the  association  was  more 
noteworthy for omeprazole.  
Conclusion: The data obtained in this study do not provide sufficient evidence to recom-
mend systematic monitoring of magnesium levels in plasma, but chronic exposure to a PPI can 
lead to severe hypomagnesaemia. 
Key words: adverse drug events, proton pump inhibitors, data mining, pharmacovigilance. 
Introduction 
In  2006,  Epstein  et  al.  reported  that  hypomag-
nesaemic  hypoparathyroidism  could  be  caused  by 
long-term  use  of  a  proton-pump  inhibitor  (PPI), 
omeprazole [1]. Thereafter, case reports accumulated, 
in which PPIs were shown to be associated with hy-
pomagnesaemia [2-11], and in 2011, the US Food and 
Ivyspring  
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Drug  Administration  (FDA)  published  a  safety  an-
nouncement  that  long-term  use  of  PPIs  can  lead  to 
hypomagnesaemia  [12].  Although  recognized  as  a 
rare side effect of PPIs, hypomagnesaemia is a serious 
condition that can be complicated by life-threatening 
arrhythmias  and  neurologic  manifestations  [10,  11]. 
Exactly how PPIs could cause hypomagnesaemia has 
not been clarified, and controlled studies are required 
to delineate the mechanisms [13]. Hypocalcaemia and 
hypokalaemia are often documented as accompany-
ing electrolyte disorders [10, 11]. Symptoms include 
tetany,  seizures,  muscle  cramps,  vomiting,  nausea, 
and diarrhea, but these are not always found in pa-
tients with hypomagnesaemia [10, 11].  
 Most reports on PPI-induced hypomagnesaemia 
concern omeprazole or esomeprazole, the S-isomer of 
omeprazole, but the recurrence after substitution by 
other PPIs suggests that this is a class effect commonly 
found for PPIs. The present study was performed to 
assess omeprazole and esomeprazole in terms of sus-
ceptibility  to  hypomagnesaemia,  and  to  this  end, 
more  than  a  million  case  reports  on  adverse  drug 
events submitted to the FDA database were reviewed. 
 
Methods 
Data sources 
Input  data  for  this  study  were  taken  from  the 
public release of the data in the FDA’s Adverse Event 
Reporting  System  (AERS),  which  covers  the  period 
from the first quarter of 2004 through the end of 2009. 
The total number of reports used was 2,231,029. This 
database  relies  on  spontaneous  reports  of  adverse 
drug events by health professionals, consumers, and 
manufacturers. The data structure of AERS is in com-
pliance with international safety reporting guidance 
ICH E2B issued by the International  Conference on 
Harmonisation, consisting of 7 data sets: patient de-
mographic and administrative information (DEMO), 
drug/biologic  information  (DRUG),  adverse  drug 
events  (REAC),  patient  outcomes  (OUTC),  report 
sources  (RPSR),  drug  therapy  start  and  end  dates 
(THER),  and  indications  for  use/diagnosis  (INDI). 
The adverse  drug events in REAC are coded  using 
preferred terms (PTs) in the Medical Dictionary for 
Regulatory  Activities  (MedDRA)  terminology. 
MedDRA ver.13.0 was used in this study. 
Prior  to  analysis,  all  drug  names  were  unified 
into  generic  names  by  a  text-mining  approach,  be-
cause AERS permits the registering of arbitrary drug 
names,  including  trade  names  and  abbreviations. 
Spelling errors were detected by a spell checker soft-
ware,  GNU  Aspell,  and  carefully  confirmed  by 
working pharmacists. The total number of errors was 
223,239. Foods, beverages, treatments (e.g. X-ray ra-
diation),  and  unspecified  names  (e.g.  beta-blockers) 
were omitted for this study, and the total number of 
omissions  was  164,384.  Finally,  duplicated  reports 
were deleted according to the FDA's recommendation 
of adopting the most recent CASE number, resulting 
in a reduction in the number of reports from 2,231,029 
to 1,644,220. A total of 22,017,956 co-occurrences were 
found in 1,644,220 reports, where a co-occurrence was 
a pair of a drug and an adverse drug event.  
Data mining  
In pharmacovigilance analyses, data mining al-
gorithms have been developed to identify an associa-
tion between a drug and an adverse drug event or a 
drug-associated adverse drug event as a signal that is 
reported more frequently than expected by estimating 
expected reporting frequencies on the basis of infor-
mation on all drugs and all adverse drug events in a 
database  [14-20].  For  example,  the  proportional  re-
porting  ratio  (PRR)  [14],  the  reporting  odds  ratio 
(ROR) [15], the information component (IC) [16], and 
the empirical Bayes geometric mean (EBGM) [17] are 
widely used. Indeed, the PRR is currently used by the 
UK  Medicines  and  Healthcare  products  Regulatory 
Agency (MHRA), the ROR by the Netherlands Phar-
macovigilance  Centre,  the  IC  by  the  World  Health 
Organization (WHO), and the EBGM by the FDA.  
All of these algorithms extract decision rules for 
signal detection and/or calculate scores to measure an 
association between a drug and an adverse drug event 
from a two-by-two frequency table of counts that in-
volve the presence or absence of a particular drug and 
a particular adverse drug event occurring in case re-
ports.  These  algorithms,  however,  differ  from  one 
another  in  that  the  PRR  and  ROR  are  frequentist 
(non-Bayesian) ones, whereas the IC and EBGM are 
Bayesian  ones.  In  this  section,  only  the  scoring 
thresholds used in the present study are given, and 
the reader is referred to review articles for more ex-
tensive details of each statistical test [18-20]. 
In  this  section,  we  define  how  the  association 
between a drug and an adverse drug event is classi-
fied as a signal, when using each statistical test. Using 
the  PRR,  a  signal  is  detected  if  the  count  of 
co-occurrences is 3 or more, and the PRR is 2 or more 
with an associated χ2 value of 4 or more [14]. For the 
ROR, a signal is detected if the lower bound of the 
95% two-sided confidence interval of ROR exceeds 1 
[15]. Signal detection using the IC is done using the 
IC025 metric, a criterion indicating the lower bound of 
the 95% two-sided confidence interval of the IC, and a 
signal is detected if the IC025  value exceeds 0 [16]. Int. J. Med. Sci. 2012, 9 
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Finally, the EB05 metric, a lower one-sided 95% con-
fidence limit  of EBGM [17], is used and a  signal  is 
detected when EB05  is greater than or equal to the 
threshold  value  2.  In  this  study,  the  adverse  drug 
events coded by PT numbers were listed as omepra-
zole- and esomeprazole-associated, when at least 1 of 
4 indices met the criteria indicated above, and sub-
sequently hypomagnesaemia was identified by the PT 
code number 10021027. 
 
Results 
 The  total  number  of  co-occurrences  with 
omeprazole  and  esomeprazole  was  178,766  and 
121,506,  representing  0.812%  and  0.552%  of  all 
co-occurrences in the database, respectively. In total, 
818  and  743  adverse  drug  events  were  listed  as 
omeprazole-  and  esomeprazole-associated  with 
55,904 and 48,481 co-occurrences, respectively.  
 Hypomagnesaemia  ranked  85th  among  818 
omeprazole-associated adverse drug events, and 135th 
among 743 for esomeprazole. The statistical data on 
omeprazole-  and  esomeprazole-associated  hypo-
magnesaemia  are  listed  in  Table  1.  An  association 
with hypomagnesaemia was suggested for both PPIs, 
but  the  association  was  more  noteworthy  for 
omeprazole. 
 
Discussion 
 Magnesium is an essential factor implicated in 
many  biochemical  and  physiological  processes,  and 
its homeostasis is sophisticatedly regulated by intes-
tinal absorption, renal excretion and other systems in 
the  body  [10,  11].  Hypomagnesaemia  or  hy-
permagnesaemia  may  arise  from  various  types  of 
disorders [10, 11]. In 2006, a report was published by 
Epstein et al., in which a PPI, omeprazole, was shown 
to be associated with hypomagnesaemia [1]. To date, 
about 10 case reports have been published with re-
spect to PPI-associated hypomagnesaemia [2-9], and 
their findings can be summarized as; 1) PPI long-term 
use was observed in patients with hypomagnesaemia, 
2) symptoms did not occur until plasma  concentra-
tions were less than 0.5 mmol/L, 3) mechanisms by 
which  the  hypomagnesaemia  occurred  under  PPI 
therapy  remain  unclear,  4)  hypokalaemia  often  ac-
companied the hypomagnesaemia, 5) hypocalcaemia 
also  frequently  developed  via  impairment  of  para-
thyroid hormone secretion, 6) oral or parenteral sup-
plement  of  magnesium  was  effective  for  temporary 
relief from symptoms, but unable to correct the plas-
ma concentration of magnesium, and 7) withdrawal of 
PPI allowed to resolve the hypomagnesaemia [10, 11]. 
Hypomagnesaemia  is  understood  to  be  a  rare  side 
effect of PPIs, but Epstein et al. speculated that the 
cases  represented  the  tip  of  an  iceberg  [1].  Hypo-
magnesaemia might be underdiagnosed, in part, due 
to the relatively low frequency of magnesium meas-
urements  in  routine  clinical  analysis.  If  hypomag-
nesaemia is found in PPI users, it might be attributed 
to  co-administered  diuretics  or  other  nephrotoxic 
drugs. It is  important to  perform clinical studies to 
clarify  the  true  prevalence  and  risk  factors,  and  to 
clarify the mechanisms by which hypomagnesaemia 
develops. 
 
 
 
 
Table 1. Signal detection for omeprazole- and esomeprazole-associated hypomagnesaemia. 
  N  PRR  
(χ2) 
ROR  
(95% two-sided CI) 
IC  
(95% two-sided CI) 
EBGM  
(95% one-sided CI) 
Omeprazole  158 
2.723 * 
(171.816) 
2.762 * 
(2.359, 3.165) 
1.424 * 
(1.197, 1.651) 
2.650 * 
(2.321) 
Esomeprazole  58 
1.470 
(8.299) 
1.474 * 
(1.138, 1.810) 
0.532 * 
(0.161, 0.903) 
1.425 
(1.146) 
N: the number of co-occurrences.  
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean.  
CI: the confidence interval; two-sided for ROR and IC, and one-sided for EBGM. 
*: signal detected, and a signal means a drug-associated adverse drug event (see “Methods” for the criteria of detection).  
The hypomagnesaemia was coded as PT10021027. 
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To  date,  most  case  reports  on  PPI-associated 
hypomagnesaemia  concern  omeprazole  or 
esomeprazole,  but  hypomagnesaemia  is  understood 
to  be  common  for  PPIs.  Broeren  et  al.  showed  that 
hypomagnesaemia  was  resolved  after  the  replace-
ment of omeprazole with a H2-blocker, ranitidine, but 
the  re-replacement  of  ranitidine  with  pantoprazole 
resulted in recurrence [5]. The same fluctuation was 
found  for  lansoprazole  [5].  Hoorn  et  al.  reported  a 
case of hypomagnesaemia in which the patient was 
treated with pantoprazole [8]. They also documented 
another case in which the replacement of omeprazole 
with rabeprazole resulted in a further decrease in se-
rum  levels  of  magnesium  [8].  In  this  study,  using 
1,644,220 reports from 2004 to 2009, it was suggested 
that hypomagnesaemia was associated with omepra-
zole and esomeprazole, and was more noteworthy for 
omeprazole,  suggesting  the  usefulness  of  the  AERS 
database  and  official  pharmacovigilance  tools.  Alt-
hough  pantoprazole,  lansoprazole  and  rabeprazole 
were  also  analyzed,  the  numbers  of  co-occurrences 
were  not  large  enough  to  detect  signals.  The  first 
clinical  report  on  PPI-associated  hypomagnesaemia 
appeared in late 2006, which was on omeprazole and 
esomeprazole,  and  the  PPI-associated  hypomag-
nesaemia entered clinical  consciousness slowly. The 
AERS data used in this study were those from 2004 to 
2009, and the latest data should be used to assess the 
associations  with  pantoprazole,  lansoprazole  and 
rabeprazole. 
The AERS database is considered a valuable tool; 
however,  some  limitations  inherent  to  spontaneous 
reporting have been pointed out [18]. First, the data 
occasionally  contain  misspelling  and  miswords,  alt-
hough the structure of AERS is in compliance with the 
international  safety  reporting  guidance.  Second,  the 
system was started more than 10 years ago, and re-
porting patterns have changed over time. Third, the 
adverse events are coded using hierarchical terms of 
PTs  of  MedDRA,  and  changes  in  terminology  over 
time also might affect the quality of the database. Last, 
there are a number of duplicate entries in the data-
base.  To  overcome  problems  with  data  quality,  we 
manually corrected mistakes in the data entities and 
deleted duplicates according to FDA’s recommended 
method, resulting in the development of a novel sys-
tem to analyze an association between a drug and an 
adverse drug event. Previously, this system has been 
used to assess adverse drug events accompanying the 
use of platinum agents [21]. The data obtained was 
consistent with clinical observations, suggesting the 
usefulness of the system [21]. Additionally, this sys-
tem was used to evaluate susceptibility to hypersen-
sitivity reactions for 14 anticancer agents, and it was 
found that the number of co-occurrences was an im-
portant  factor  in  signal  detection  [22,  23].  Very  re-
cently, this system was applied to the evaluation of 
adverse drug events induced by statins [24], capecit-
abine [25] and tigecycline [26], and again the repro-
ducibility  of  clinical  observations  was  suggested, 
providing  that  the  number  of  co-occurrences  was 
large enough to detect a signal.  
 It  should  be  noted  that  there  is  no  credible 
counterfactual  means,  e.g.,  a  randomized  control 
group, to identify an association between a drug and 
an adverse drug event as a signal, and therefore dis-
ease-oriented adverse events can be extracted as sig-
nals. For example, hypomagnesaemia was extracted 
as an omeprazole-associated adverse drug event, but 
might be common in patients with acid peptic disor-
ders irrespective of the administration of PPIs. Gen-
erally, the results obtained using this system can be 
biased  by  unmeasured  confounding  factors,  and 
flawed  by  incomplete  data;  however,  a  comparison 
among  PPIs  possibly  offsets  them,  resulting  in  a 
rank-order of association according to the statistical 
metrics. In conclusion, the data obtained in this study 
do  not  provide  sufficient  evidence  to  recommend 
systematic monitoring of magnesium levels in plas-
ma, but chronic exposure to a PPI can lead to severe 
hypomagnesaemia. 
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